Review



polyclonal goat anti human bcma ab  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems polyclonal goat anti human bcma ab
    Polyclonal Goat Anti Human Bcma Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human bcma ab/product/R&D Systems
    Average 94 stars, based on 14 article reviews
    polyclonal goat anti human bcma ab - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    94
    R&D Systems polyclonal goat anti human bcma ab
    Polyclonal Goat Anti Human Bcma Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human bcma ab/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    polyclonal goat anti human bcma ab - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    R&D Systems polyclonal goat anti human bcma antibody
    Fig. 1. Mechanism of drug action and impact of sBCMA. (A) <t>BCMA</t> CD3 bispecific antibody binds to membrane-bound BCMA on MM cells and CD3 on T cells. (B) sBCMA in the central compartment can compete with membrane-bound BCMA for binding to the drug, thereby producing a sink that can reduce the efficacious drug concentration. Levels of the soluble form may also be used as a biomarker for disease progression. BCMA, B cell maturation antigen; MM, multiple myeloma; sBCMA, soluble BCMA.
    Polyclonal Goat Anti Human Bcma Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human bcma antibody/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    polyclonal goat anti human bcma antibody - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    R&D Systems polyclonal goat anti human bcma
    Fig. 1. Mechanism of drug action and impact of sBCMA. (A) <t>BCMA</t> CD3 bispecific antibody binds to membrane-bound BCMA on MM cells and CD3 on T cells. (B) sBCMA in the central compartment can compete with membrane-bound BCMA for binding to the drug, thereby producing a sink that can reduce the efficacious drug concentration. Levels of the soluble form may also be used as a biomarker for disease progression. BCMA, B cell maturation antigen; MM, multiple myeloma; sBCMA, soluble BCMA.
    Polyclonal Goat Anti Human Bcma, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human bcma/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    polyclonal goat anti human bcma - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 1. Mechanism of drug action and impact of sBCMA. (A) BCMA CD3 bispecific antibody binds to membrane-bound BCMA on MM cells and CD3 on T cells. (B) sBCMA in the central compartment can compete with membrane-bound BCMA for binding to the drug, thereby producing a sink that can reduce the efficacious drug concentration. Levels of the soluble form may also be used as a biomarker for disease progression. BCMA, B cell maturation antigen; MM, multiple myeloma; sBCMA, soluble BCMA.

    Journal: Assay and drug development technologies

    Article Title: A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug.

    doi: 10.1089/adt.2020.1024

    Figure Lengend Snippet: Fig. 1. Mechanism of drug action and impact of sBCMA. (A) BCMA CD3 bispecific antibody binds to membrane-bound BCMA on MM cells and CD3 on T cells. (B) sBCMA in the central compartment can compete with membrane-bound BCMA for binding to the drug, thereby producing a sink that can reduce the efficacious drug concentration. Levels of the soluble form may also be used as a biomarker for disease progression. BCMA, B cell maturation antigen; MM, multiple myeloma; sBCMA, soluble BCMA.

    Article Snippet: Polyclonal goat anti-human BCMA antibody (R&D Systems) and polyclonal rabbit anti-peptide (CSSTPPLTCQR) antibodies (Cambridge Research Biochemicals) were buffer exchanged into phosphate-buffered saline (PBS), pH 7.4 (Gibco, Grand Island, NY) using a Zeba spin desalting column, 40 k MWCO (Thermo Scientific) following the manufacturer’s instructions.

    Techniques: Membrane, Binding Assay, Concentration Assay, Biomarker Discovery

    Fig. 2. BCMA CD3 bispecific antibody interferes extensively with measurement of total sBCMA by LBA. Four concentrations of BCMA CD3 bispecific antibody (blue squares =no spike, red triangle = 0.069 nM, inverted green triangle = 0.55 nM, purple diamond =6.9 nM, orange circle = 55 nM) were spiked into: (A) QCs prepared by spiking recombinant monkey sBCMA into surrogate matrix at 75.2, 8.84, 1.04, 0.12 nM (denoted HQC, MQC, LQC, and LLOQ, respectively) and (B) four naive cynomolgus monkey plasma samples with endogenous sBCMA. As the drug concentrations increased, the re- covered amount of sBCMA rapidly decreased. HQC, high quality control; LBA, ligand binding assay; LLOQ, lower limit of quantitation; LQC, low quality control; MQC, mid quality control.

    Journal: Assay and drug development technologies

    Article Title: A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug.

    doi: 10.1089/adt.2020.1024

    Figure Lengend Snippet: Fig. 2. BCMA CD3 bispecific antibody interferes extensively with measurement of total sBCMA by LBA. Four concentrations of BCMA CD3 bispecific antibody (blue squares =no spike, red triangle = 0.069 nM, inverted green triangle = 0.55 nM, purple diamond =6.9 nM, orange circle = 55 nM) were spiked into: (A) QCs prepared by spiking recombinant monkey sBCMA into surrogate matrix at 75.2, 8.84, 1.04, 0.12 nM (denoted HQC, MQC, LQC, and LLOQ, respectively) and (B) four naive cynomolgus monkey plasma samples with endogenous sBCMA. As the drug concentrations increased, the re- covered amount of sBCMA rapidly decreased. HQC, high quality control; LBA, ligand binding assay; LLOQ, lower limit of quantitation; LQC, low quality control; MQC, mid quality control.

    Article Snippet: Polyclonal goat anti-human BCMA antibody (R&D Systems) and polyclonal rabbit anti-peptide (CSSTPPLTCQR) antibodies (Cambridge Research Biochemicals) were buffer exchanged into phosphate-buffered saline (PBS), pH 7.4 (Gibco, Grand Island, NY) using a Zeba spin desalting column, 40 k MWCO (Thermo Scientific) following the manufacturer’s instructions.

    Techniques: Recombinant, Clinical Proteomics, Control, Ligand Binding Assay, Quantitation Assay

    Fig. 3. Protein-level IA-LC-MS/MS workflow and minimization of drug interference. (A) sBCMA was captured with biotinylated polyclonal anti-BCMA antibodies, which were immunoprecipitated using streptavidin-coated magnetic beads. Beads were washed, bound sBCMA was eluted, and eluates were processed to generate tryptic peptides that were analyzed by LC-MS/MS. (B) Suppression of peak area in the presence of BCMA CD3 bispecific antibody relative to the unspiked condition was overcome by titrating the capture antibody. IA, im- munoaffinity; LC-MS/MS, liquid chromatography–tandem mass spectrometry.

    Journal: Assay and drug development technologies

    Article Title: A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug.

    doi: 10.1089/adt.2020.1024

    Figure Lengend Snippet: Fig. 3. Protein-level IA-LC-MS/MS workflow and minimization of drug interference. (A) sBCMA was captured with biotinylated polyclonal anti-BCMA antibodies, which were immunoprecipitated using streptavidin-coated magnetic beads. Beads were washed, bound sBCMA was eluted, and eluates were processed to generate tryptic peptides that were analyzed by LC-MS/MS. (B) Suppression of peak area in the presence of BCMA CD3 bispecific antibody relative to the unspiked condition was overcome by titrating the capture antibody. IA, im- munoaffinity; LC-MS/MS, liquid chromatography–tandem mass spectrometry.

    Article Snippet: Polyclonal goat anti-human BCMA antibody (R&D Systems) and polyclonal rabbit anti-peptide (CSSTPPLTCQR) antibodies (Cambridge Research Biochemicals) were buffer exchanged into phosphate-buffered saline (PBS), pH 7.4 (Gibco, Grand Island, NY) using a Zeba spin desalting column, 40 k MWCO (Thermo Scientific) following the manufacturer’s instructions.

    Techniques: Liquid Chromatography with Mass Spectroscopy, Immunoprecipitation, Magnetic Beads, Liquid Chromatography, Mass Spectrometry

    Fig. 5. Total sBCMA levels in cynomolgus monkeys dosed with bispecific antibody and in un- treated human MM patients. (A) Concentration of total plasma sBCMA increases after dosing with BCMA CD3 bispecific antibody (blue circle = 1 mg/kg, red square = 10 mg/kg, and green triangle = 100 mg/kg). (B) Concentration of sBCMA in plasma samples from relapsed/refractory MM patients. sBCMA level in pooled normal plasma sample depicted by dotted line (1.75 nM).

    Journal: Assay and drug development technologies

    Article Title: A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug.

    doi: 10.1089/adt.2020.1024

    Figure Lengend Snippet: Fig. 5. Total sBCMA levels in cynomolgus monkeys dosed with bispecific antibody and in un- treated human MM patients. (A) Concentration of total plasma sBCMA increases after dosing with BCMA CD3 bispecific antibody (blue circle = 1 mg/kg, red square = 10 mg/kg, and green triangle = 100 mg/kg). (B) Concentration of sBCMA in plasma samples from relapsed/refractory MM patients. sBCMA level in pooled normal plasma sample depicted by dotted line (1.75 nM).

    Article Snippet: Polyclonal goat anti-human BCMA antibody (R&D Systems) and polyclonal rabbit anti-peptide (CSSTPPLTCQR) antibodies (Cambridge Research Biochemicals) were buffer exchanged into phosphate-buffered saline (PBS), pH 7.4 (Gibco, Grand Island, NY) using a Zeba spin desalting column, 40 k MWCO (Thermo Scientific) following the manufacturer’s instructions.

    Techniques: Concentration Assay, Clinical Proteomics